Proton magnetic resonance spectroscopy in the evaluation of children with congenital heart disease and acute central nervous system injury.
We studied nine infants and children, aged 1 week to 42 months, with severe acute central nervous system injuries associated with cardiac disease or corrective operations by means of single-voxel proton magnetic resonance spectroscopy to determine whether this technique would be useful in predicting neurologic outcome. Proton magnetic resonance spectroscopic data were acquired from the occipital gray and parietal white matter (8 cm3 volume, stimulated echo-acquisition mode sequence with echo time of 20 msec and repetition time of 3.0 seconds) a median of 9 days after operation (range 3 to 42 days). Data were expressed as ratios of areas under metabolite peaks, including N-acetyl compounds, choline-containing compounds, creatine and phosphocreatine, and lactate. Four patients had cerebral insults before operation, one had both a preoperative and a perioperative insult, three had perioperative insults, and one had a prolonged cardiac arrest 2 days after operation. Outcomes (Glasgow Outcome Scale scores) were assigned at discharge and 6 to 12 months after injury. Six patients were in a vegetative state or had severe impairment at discharge, and two still had severe impairment at 6- to 12-month follow-up. Proton magnetic resonance spectroscopy showed lactate in these two patients, along with markedly reduced ratios of N-acetyl compounds to creatine compounds. The other four patients with severe impairment recovered to a level of mild disability at follow-up. Proton magnetic resonance spectroscopy showed no lactate in these four patients; however, one patient showed moderately reduced ratio of N-acetyl compounds to creatine compounds. The three patients who had mild or moderate impairment at discharge showed no lactate and mild or no changes in metabolite ratios; follow-up revealed normal or mild outcomes. Overall, we found that the presence of lactate and markedly reduced ratios of N-acetyl compounds to creatine compounds were predictive of severe outcomes at discharge and long-term follow-up, whereas no lactate and mild or no changes in ratios suggested potential for recovery with at least a mild disability. Continuing investigations are in progress to determine the optimal selection of candidates and timing of proton magnetic resonance spectroscopic studies.
Ashwal
S
S
Department of Pediatrics, Loma Linda University School of Medicine, CA 92354, USA.
Holshouser
B A
BA
Hinshaw
D B
DB
Schell
R M
RM
Bailey
L
L
D001224:Aspartic Acid / Q000031:analogs & derivatives / Q000378:metabolism; D001921:Brain / Q000378:metabolism; D001930:Brain Injuries / Q000209:etiology* / Q000378:metabolism; D002315:Cardiopulmonary Bypass; D016022:Case-Control Studies; D002675:Child, Preschool; D002794:Choline / Q000378:metabolism; D003128:Coma / Q000209:etiology / Q000378:metabolism; D003401:Creatine / Q000378:metabolism; D005500:Follow-Up Studies; D005544:Forecasting; D015600:Glasgow Coma Scale; D006323:Heart Arrest / Q000150:complications; D006330:Heart Defects, Congenital / Q000150:complications* / Q000601:surgery; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007773:Lactates / Q000378:metabolism; D009682:Magnetic Resonance Spectroscopy; D009460:Neurologic Examination; D010351:Patient Discharge; D010725:Phosphocreatine / Q000378:metabolism; D011522:Protons; D016896:Treatment Outcome
D007773:Lactates; D011522:Protons; D010725:Phosphocreatine; D001224:Aspartic Acid; C000179:N-acetylaspartate; D003401:Creatine; D002794:Choline